Assessment of therapeutic response in patients with metastatic bone disease.
Metastatic bone disease is common in cancer patients and causes substantial disease-related morbidity and mortality. However, several effective treatments are available for the management of these patients. Bisphosphonates, which inhibit osteoclast-mediated resorption of bone matrix, are especially important because they decrease the incidence of skeletal-related events in many tumour types and can complement antineoplastic therapies. At present, assessment of treatment for bone metastases is hindered by a lack of effective, rapid methods to measure disease response. We discuss the difficulties of current measures of response assessment and describe the development of new radiological and biochemical markers of bone metastases. Assays that detect type I collagen telopeptides as markers of bone resorption seem to be most promising at present.
Cancer Research UK, Department of Medical Oncology, Christie Hospital, Manchester, UK.
Andrew
A
Clamp
Sarah
S
Danson
Huy
H
Nguyen
David
D
Cole
Mark
M
Clemons
D015502:Absorptiometry, Photon; D014408:Biomarkers, Tumor / Q000097:blood; D001859:Bone Neoplasms / Q000556:secondary* / Q000628:therapy*; D016723:Bone Remodeling; D006801:Humans; D008279:Magnetic Resonance Imaging; D014055:Tomography, Emission-Computed; D014057:Tomography, X-Ray Computed; D016896:Treatment Outcome
D014408:Biomarkers, Tumor